APSR2026-364

Yes
Late-Breaking
Submitted
Oral Presentation
AO17-002
 
 
https://storage.unitedwebnetwork.com/files/1285/1219525-46903-APSR 2026-364 _Oral_433566.pptx
Format: PPTX Only
 
Format: PDF Only
07. COPD
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Kuang-Ming Liao * Chi Mei Medical Center, Chiali Division of Chest Medicine/Department of Internal Medicin Tainan Taiwan
Chung-Han Ho - Chi Mei Medical Center Department of Medical Research Tainan Taiwan
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Kuang-Ming
Liao
abc8870@yahoo.com.tw
+886910664560
41-50
Taiwan
Original Research
The Risk of Major Adverse Cardiac Event in Patients with Chronic Obstructive Pulmonary Disease and Diabetes Received Dipeptidyl Peptidase-4 Inhibitors
Maximum 25 words
Abstract Content
Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory disorder frequently accompanied by cardiovascular disease and diabetes mellitus (DM), both of which substantially increase the risk of major adverse cardiovascular events (MACE). Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used antidiabetic agents with potential anti-inflammatory and cardiovascular protective effects beyond glycemic control. We investigated whether DPP-4 inhibitor use is associated with a reduced risk of MACE in patients with COPD and comorbid DM.
We conducted a nationwide retrospective cohort study using Taiwan’s National Health Insurance Research Database from January 1, 2016, to December 31, 2021. Patients aged ≥40 years with at least one hospitalization for COPD and a diagnosis of DM were included. DPP-4 inhibitor users were identified by prescription records (ATC code A10BH*), and non-users were defined as patients receiving other antidiabetic agents without DPP-4 inhibitors. The primary outcome was MACE, defined as a composite of cardiovascular death, myocardial infarction, and stroke. Cox proportional hazards models were used to estimate crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs), adjusting for demographic characteristics and comorbidities.
A total of 24,215 patients with COPD and DM were included, of whom 5,737 (23.7%) were DPP-4 inhibitor users and 18,478 (76.3%) were non-users. During follow-up, DPP-4 inhibitor users had a significantly lower incidence of MACE compared with non-users (17.88% vs. 26.34%, p < 0.0001). In multivariable analysis, non–DPP-4 inhibitor use was associated with a higher risk of MACE (adjusted HR: 1.56; 95% CI: 1.46–1.67; p < 0.0001). The protective association of DPP-4 inhibitors was consistent across sex, age groups, and patients with prior myocardial infarction, stroke, or hypertension.
In patients with COPD and comorbid DM, DPP-4 inhibitor use was associated with a significantly lower risk of MACE. These findings suggest that DPP-4 inhibitors may provide cardiovascular benefits beyond glycemic control in this high-risk population. Randomized controlled trials are warranted to confirm causality.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Chronic obstructive pulmonary disease, dipeptidyl peptidase-4 inhibitor, major adverse cardiovascular events.
maximum 3 keywords and no abbreviations, separated by commas
 
322